Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

ORIC starts Phase 3 Himalayas-1 of rinzimetostat with Bayer's darolutamide in mCRPC

The company reported third-quarter 2026 results as it launched a global Phase 3 trial in post-abiraterone metastatic castration-resistant prostate cancer, following End-of-Phase 1 talks with regulators.

16 Nov 2026 · Oric Pharmaceuticals, Inc. ORIC · Company news

ORIC Pharmaceuticals said on 16 November 2026 that it has started Himalayas-1, a global Phase 3 trial of rinzimetostat combined with Bayer's darolutamide in metastatic castration-resistant prostate cancer (mCRPC) after prior abiraterone treatment. The announcement came alongside the company's third-quarter 2026 financial results.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Oric Pharmaceuticals, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →